Impact on Reducing the Incidence of Low Serum Calcium by Providing Educational Materials on the Need to Take Daily Supplemental Calcium and Vitamin D to Patients With Paget's Disease Treated With Reclast®

Completed · Phase 4

Conditions studied: Paget's Disease of the Bone, Hypocalcemia

In brief

This study will evaluate the impact of investigator and patient education and educational materials to foster calcium and vitamin D supplementation to mitigate the potential for hypocalcemia post Reclast® administration in patients with Paget's disease of bone.

Key facts

Study ID

NCT00668200

Run by

Novartis Pharmaceuticals

People needed

81

Starts

2008-05-01

Expected to finish

2012-11-01

Last updated by the study team

2015-03-06

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Written informed consent
• As per currently approved Reclast® Package Insert:

You may not qualify if…

• As per currently approved Reclast® Package Insert:

Where it is running

• Novartis Investigative Site — Phoenix, Arizona, United States
• Novartis Investigative Site — Tucson, Arizona, United States
• Novartis Investigative Site — Gainesville, Georgia, United States
• Novartis Investigative Site — Detroit, Michigan, United States
• Novartis Investigative Site — Syracuse, New York, United States
• Novartis Investigative Site — Providence, Rhode Island, United States
• Novartis Investigative Site — Dallas, Texas, United States
• Novartis Investigative Site — Waco, Texas, United States
• Novartis Investigative Site — Madison, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.